|0.575 0.035 (6.48%)||12-07 16:00|
|Targets||6-month :||0.99||1-year :||1.27|
|Resists||First :||0.84||Second :||1.09|
|Supports||First :||0.45||Second :||0.38|
|MAs||MA(5) :||0.55||MA(20) :||0.66|
|MA(100) :||1.04||MA(250) :||1.12|
|MACD||MACD :||-0.2||Signal :||-0.2|
|%K %D||K(14,3) :||21.2||D(3) :||17.3|
|52-week||High :||1.75||Low :||0.45|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ FIXX ] has closed below upper band by 7.8%. Bollinger Bands are 82% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||0.59 - 0.59||0.59 - 0.6|
|Low:||0.52 - 0.53||0.53 - 0.53|
|Close:||0.57 - 0.57||0.57 - 0.58|
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||58 (M)|
|Held by Insiders||3.091e+007 (%)|
|Held by Institutions||9.1 (%)|
|Shares Short||307 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-5 %|
|Return on Assets (ttm)||984.7 %|
|Return on Equity (ttm)||-36.4 %|
|Qtrly Rev. Growth||1.96e+006 %|
|Gross Profit (p.s.)||-2795|
|Sales Per Share||-3667.5|
|Qtrly Earnings Growth||-2.3 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-102 (M)|
|Price to Book value||0|
|Price to Sales||-0.01|
|Price to Cash Flow||-0.01|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|